

**RECEIVED  
CENTRAL FAX CENTER**

NOV 07 2006

Attorney Docket No.: 6409.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Eberhard Draeger

Confirmation No.: 6304

Application No.: 10/721,710

Group Art Unit: 1654

Filed: November 25, 2003

Examiner: Khanna, Hemant

For: Insulin Administration Regimens For The Treatment Of Subjects With Diabetes

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


This paper is being filed in response to the Notice to File Restriction Requirement mailed October 3, 2006 that made restriction and election of species requirements. Applicants were requested to elect one of III designated Groups and if Groups I or III were elected, to elect a species from claim 7 (Group I) or from claims 25, 29 or 43 (Group III).

In response to these requirements, Applicants hereby elect with traverse the invention the claims of Group II, claims 11-16. Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: November 7, 2006

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

**23650**

PATENT TRADEMARK OFFICE